Farrow Jeffrey S — SEC insider filings

SEC reporting owner CIK 1405253. 25 insider filings on record with FilingPulse; latest filed 2026-10-15.

Transaction summary — filings shown

Covers all 25 filings on record, filed 2021-02-03 to 2026-10-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Tarsus Pharmaceuticals, Inc. (TARS)See Remarks11—9 legs · 48,603 sh · $2,332,26819
Global Blood Therapeutics, Inc. (GBT)Chief Financial Officer11—1 leg · 31,441 sh · $2,137,98857
ACHIEVE LIFE SCIENCES, INC. (ACHV)Director2——3
LISATA THERAPEUTICS, INC. (LSTA)Director1———

Insider filings — Farrow Jeffrey S

FiledFormIssuerReported transactionsSource
2026-10-153LISATA THERAPEUTICS, INC. (LSTA)Holdings only — no transactions reportedEDGAR
2026-07-294ACHIEVE LIFE SCIENCES, INC. (ACHV)Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 16,700 (derivative) @ $0EDGAR
2026-06-174Tarsus Pharmaceuticals, Inc. (TARS)Option exercise (M): 27,881 · Sale (S): 14,396 @ $60.95 · Option exercise (M): 27,881 (derivative) @ $0EDGAR
2026-06-024ACHIEVE LIFE SCIENCES, INC. (ACHV)Grant/award (A): 47,250 (derivative) @ $0EDGAR
2026-03-194Tarsus Pharmaceuticals, Inc. (TARS)Sale (S): 2,111 @ $69.42 · Sale (S): 2,133 @ $68.71 · Sale (S): 2,186 @ $67EDGAR
2026-03-174Tarsus Pharmaceuticals, Inc. (TARS)Option exercise (M): 13,042 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0EDGAR
2026-03-094Tarsus Pharmaceuticals, Inc. (TARS)Grant/award (A): 30,724 (derivative) @ $0 · Grant/award (A): 19,306 (derivative) @ $0EDGAR
2025-06-184Tarsus Pharmaceuticals, Inc. (TARS)Option exercise (M): 27,881 · Sale (S): 13,608 @ $40.42 · Option exercise (M): 27,881 (derivative) @ $0EDGAR
2025-03-204Tarsus Pharmaceuticals, Inc. (TARS)Sale (S): 1,284 @ $46.29 · Sale (S): 1,254 @ $47.40 · Sale (S): 1,186 @ $50.11EDGAR
2025-03-184Tarsus Pharmaceuticals, Inc. (TARS)Option exercise (M): 8,019 · Option exercise (M): 8,019 (derivative) @ $0EDGAR
2025-03-074Tarsus Pharmaceuticals, Inc. (TARS)Grant/award (A): 30,628 (derivative) @ $0 · Grant/award (A): 20,089 (derivative) @ $0EDGAR
2024-06-204Tarsus Pharmaceuticals, Inc. (TARS)Option exercise (M): 27,881 · Sale (S): 10,445 @ $27.47 · Option exercise (M): 27,881 (derivative) @ $0EDGAR
2024-03-114Tarsus Pharmaceuticals, Inc. (TARS)Grant/award (A): 47,500 (derivative) @ $0 · Grant/award (A): 32,079 (derivative) @ $0EDGAR
2023-04-264Tarsus Pharmaceuticals, Inc. (TARS)Grant/award (A): 163,397 (derivative) @ $0 · Grant/award (A): 111,525 (derivative) @ $0EDGAR
2022-10-064Global Blood Therapeutics, Inc. (GBT)Disposition to issuer (D): 26,739 · Disposition to issuer (D): 3,125 (derivative) · Disposition to issuer (D): 9,060 (derivative) · Disposition to issuer (D): 13,814 (derivative) · Disposition to issuer (D): 15,460 (derivative) · Disposition to issuer (D): 26,454 (derivative) · +8 moreEDGAR
2022-09-294Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 23,653 @ $16.40 · Option exercise (M): 23,653 (derivative) @ $0EDGAR
2022-09-064Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 2,763 · Option exercise (M): 2,208 · Tax withholding (F): 1,885 @ $68.15 · Sale (S): 31,441 @ $68 · Option exercise (M): 2,763 (derivative) @ $0 · Option exercise (M): 2,208 (derivative) @ $0EDGAR
2022-08-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 6,145 · Tax withholding (F): 2,126 @ $32.40 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0EDGAR
2022-03-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 2,763 · Tax withholding (F): 1,315 @ $29.87 · Option exercise (M): 2,763 (derivative) @ $0 · Grant/award (A): 17,668 (derivative) @ $0 · Grant/award (A): 17,668 (derivative) @ $0 · Grant/award (A): 28,628 (derivative) @ $0EDGAR
2022-02-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 9,020 · Tax withholding (F): 4,506 @ $29.33 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0EDGAR
2021-09-244/AGlobal Blood Therapeutics, Inc. (GBT)Option exercise (M): 9,020 · Tax withholding (F): 4,354 @ $27.33 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0EDGAR
2021-09-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 2,762 · Tax withholding (F): 1,370 @ $29.85 · Option exercise (M): 2,762 (derivative) @ $0EDGAR
2021-08-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 9,020 · Tax withholding (F): 4,354 @ $27.33 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0EDGAR
2021-03-034Global Blood Therapeutics, Inc. (GBT)Grant/award (A): 38,739 (derivative) @ $0 · Grant/award (A): 22,102 (derivative) @ $0EDGAR
2021-02-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 12,083 · Tax withholding (F): 5,865 @ $49.49 · Option exercise (M): 3,063 (derivative) @ $0 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-01-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1405253 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs